

CUMULATIVE INDEX 1993

Volume 13

March	RENAL FUNCTION, pages 1-312
June	NUTRITION SUPPORT, pages 313-530
September	PATHOPHYSIOLOGY OF THYROID DISEASE, pages 531-757
December	ROUTINE HEMATOLOGIC TESTING, pages 759-1021

Note: Page numbers of article and issue titles are in **boldface** type

- A MUDPIE mnemonic, in metabolic acidosis, 112
- Absorptiometry, in nutritional assessment, 336
- Accessory cells, in autoimmune thyroid disease, 690-694
- Accreditation programs, 513-514, 988-989
- Acid electrophoresis, hemoglobin, 804
- Acid elution technique, for fetal hemoglobin detection, 910-912
- Acid loading tests, in renal tubular acidosis, 121-122
- Acid phosphatase, determination of, prostatic, 279-284
tartrate-resistant, 918-919
- Acid-base status, 103-116
buffer regulation of, 104-105
diagnosis of, anion gap in, 109-110, 112
blood collection for, 106
Henderson equation in, 106-107
pH to hydrogen ion conversion in, 107-108
prediction of compensatory responses in, 108
normal parameters of, 103-104
perturbations in, 110-114. *See also Acidosis; Alkalosis.*
mixed, 104, 114
therapy for, 115
principles of, 103-104
systemic response in, 104-106
- Acidemia, definition of, 103
- Acidosis, definition of, 103-104
hypophosphatemia in, 195
lactic, 110
metabolic, diagnosis of, 111-113
hyperchloremic, 109-110, 112-113
hyperkalemic, 150-151
in mixed acid-base disorders, 114
potassium redistribution in, 151-152
renal tubular. *See Renal tubular acidosis.*
respiratory, diagnosis of, 113
in mixed acid-base disorders, 114
potassium redistribution in, 152
- Acquired immunodeficiency syndrome. *See Human immunodeficiency virus infection.*
- Acromegaly, hyperphosphatemia in, 189
- Activated partial thromboplastin time, in liver disease, 960
with lupus anticoagulant, 962-963
- Activity coefficient, in vitamin assay, 374
- Acute interstitial nephritis, diagnosis of, 92
- Acute lymphocytic leukemia, diagnosis of, flow cytometry in, 838-839
- Acute mixed lineage leukemias, diagnosis of, flow cytometry in, 840
- Acute Physiology and Chronic Health Evaluation system, in outcome prediction, 346-348
- Acute tubular necrosis, diagnosis of, 91-92
- Adrenal gland, disorders of, hypertension in, 292-297
- Adrenocorticotrophic hormone, determination of, 295
- Age, nutritional assessment in, results interpretation and, 324-325
- AIDS (acquired immunodeficiency syndrome). *See Human immunodeficiency virus infection.*
- Alanine transaminases, in vitamin assay, 376

- Albumin, abnormalities of, detection of, 594-595
 free hormone hypothesis and, 600
 in elderly persons, 348
 in nutritional assessment, 338-339, 345-346, 356-357
 in urine, 14-15
 physicochemical properties of, 586
 variations in, 591-592
- Alcoholism, hypophosphatemia in, 199
- Aldosterone, deficiency of, hyperkalemia in, 150-151
 excess of, hypertension in, 293-294
 resistance to, hyperkalemia in, 151
- Alkalemia, definition of, 103
- Alkaline electrophoresis, hemoglobin, 803-804
- Alkalosis, definition of, 103-104
 metabolic, diagnosis of, 113
 in mixed acid-base disorders, 114
 respiratory, diagnosis of, 113-114
 hypocalcemia in, 166
 hypophosphatemia in, 196-197
 in mixed acid-base disorders, 114
- Alpha-2-antiplasmin, assays for, 953
- 1-Alpha-hydroxylase deficiency, hypocalcemia in, 164-165
- Aluminum bone disease, hypercalcemia in, 171
- Aluminum intoxication, in hyperphosphatemia treatment, 191-192
- Amino acids, metabolic diseases of. See also *Phenylketonuria*.
 nutrition support in, 413-415
 requirements of, in elderly persons, 441-442
- Ammonium chloride loading test, in renal tubular acidosis, 121-122
- Analbuminemia, 592
- Anaplastic thyroid carcinoma, 726
 fine-needle aspiration in, 703
 treatment of, 730-731
- Anemia, Fanconi's, neutropenia in, 882-883
 hemolytic, diagnosis of, staining for, 912-913
 from infant formulas, 393
 iron deficiency, 395, 443-444
 red cell indices in, 777-781
 wellness testing for, 486-487
 macrocytic, red cell indices in, 781
 megaloblastic, in folic acid deficiency, 376-377
 neutropenia in, 888
 microcytic, differential diagnosis of, red cell indices in, 777-781
 mean platelet volume in, 946-947
 normocytic, red cell indices in, 781
 of prematurity, 395-396
 of senescence, 444
- Anergy, in malnutrition, 340-341
- Anesthesia, lymphocytopenia in, 929
- Aneuploidy, measurement of, flow cytometry in, 842, 844
- Angioimmunoblastic lymphadenopathy with dysproteinemia, lymphocytopenia in, 927
- Angiotensin(s), in renal function, 8
- Angiotensin converting enzyme inhibitors, 239-240, 243-244
- Anion gap, in acid-base status, 109-110, 112
 urinary, in renal tubular acidosis, 120-121
- Anionic dyes, 762
- Antacids, hypophosphatemia from, 193
- Anthropometry, in nutritional assessment, 333-334
- Antibiotics, in neutropenia, 892
- Antibodies, anticardiolipin, 963-964
 Factor VIII, 961-962
 in malnutrition, 459
- Anticoagulants, acquired circulating, 961-962
- Antidiuretic hormone, inappropriate secretion of, hyponatremia in, 138, 142
- Anti-DNA antibody measurement, in glomerular disease, 73-75
- Antilymphocyte therapy, lymphocytopenia in, 927
- Antineutrophil antibodies, in glomerular disease, 79-81
 neutropenia and, 882
- Antioxidants, for free radicals. See under *Free radicals*.
- Antiphospholipid antibodies, 963-964
- Antithrombin III, assays for, 952-953
 deficiency of, 964-965
- APACHE (Acute Physiology and Chronic Health Evaluation) system, in outcome prediction, 346-348
- Aperture impedance, in red cell analysis, 775
- Appendicitis, band count in, 898-899
 lymphocytopenia in, 928
- Arachidonic acid metabolites, in kidney function, 241-245
 in renal function, 8-9
- Arginine, in urea cycle disease, 430
- Arginine hydrochloride loading test, in renal tubular acidosis, 122
- Arm circumference, in nutritional assessment, 334
- Arteritis, temporal, erythrocyte sedimentation rate in, 794-795
- Arthritis, rheumatoid, erythrocyte sedimentation rate in, 794-795
- Ascorbic acid. See *Vitamin C*.

- Aspartic acid transaminases, in vitamin assay, 376
- Aspiration, fine-needle, of thyroid, **699-709**
in cancer diagnosis, 728-729
ultrasonographic guidance of, 716-719
- Ataxia telangiectasia, lymphocytopenia in, 926
- Atherogenesis, free radicals in, **475-480**
- Atomic absorption spectrometry, in magnesium determination, 213
- Atomic absorption spectrophotometry, in zinc determination, 382
- Autoimmune neutropenia, 888-889
- Autoimmune thyroid disease, **683-697**
autoreactive T cells in, 687
defective autoreactivity control in, 683-685
definition of, 685
Graves' disease as, 687-689
Hashimoto's thyroiditis as, 689-690
in congenital hypothyroidism, 649
iodine deficiency and, 692-694
major histocompatibility complex cells in, 690-694
self-tolerance and, 683-685
simple goiter as, 690
thyroid atrophy as, 690
thyroid autoantibodies in, 685-686
- Automation, of erythrocyte sedimentation rate, 792-793
of red cell analysis, 775-776
of thyroid function testing, **631-644**
- Auxochromes, 761-762
- Azure B-eosin complex, 767-768
- Azure stains, 760-761, 765-767
- B lymphocytes, flow cytometry studies of,**
836-838
in leukemia, 839-841
in lymphoma, 841-842
- Band count, 895-903**
alternatives to, 899-900
reference ranges for, 896-897
technical limitations of, 899
uses of, 897-899
- "Bare lymphocyte syndrome," 926
- Bartter's syndrome, 155
- Basal metabolic rate, in elderly persons, 439, 441
- Base. See *Acid-base status*.
- Basement membrane, of kidney, 3
- Bence Jones proteins, in urine, 15-16
- Benchmarking, in quality management, 522
- Benedict's test, in galactosemia, 425
- Bernard-Soulier disease, mean platelet volume in, 945
- Bessman classification, anemias, 778-779
- Beutler fluorescent spot test, in galactosemia, 425
- Bicarbonate, determination of, in hypertension, 288-289
in acid-base balance, 104-105
titration of, in renal tubular acidosis, 124-125
- Bioelectrical impedance analysis, in nutritional assessment, 337-338
- Biopsy, fine-needle aspiration, of thyroid, **699-709**
in cancer diagnosis, 728-729
ultrasonographic guidance of, 716-719
kidney, 30
in kidney failure, 97
- Biopterin, determination of, in phenylketonuria, 418
- Biotin, in metabolic disease, 427, 429-430
- Blood, hypophosphatemia effects on, 202-203
- Blood count, instruments for. See *Instrumentation, hematology*.
- Blood gas determination, instruments for, 822
- Blood pressure, elevated. See *Hypertension*.
lead effects on, **245-248**
regulation of, kallikrein-kinin system in, **235-241**
leukotrienes in, 241-244
prostaglandins in, **241-245**
thromboxanes in, 241-244
- Blood smear, review of. See *Peripheral smear review*.
- Blood testing. See *Hematologic testing*.
- Blood transfusion, hyperphosphatemia in, 187
- Blood urea nitrogen, 44
in elderly persons, 269-270
- Body composition, in nutritional assessment, 332-340
- Body conductivity, total, in nutritional assessment, 337
- Body mass index, in elderly persons, 441
- Bone, deposition of, hypocalcemia in, 165
hypophosphatemia in, 199
metabolic disease of, in neonates, 394-395
- Bone marrow, defects of, neutropenia in, 881-882
suppression of, recovery after, 889-890
- Bradykinin, in kidney function, 239-240
- Brain, edema of, in hyponatremia, 141-142
- Breast milk, nutrition and, 390-392, 394-397, 403-404
- Breathing, work of, measurement of, 343
- Bricker trade-off hypothesis, in renal failure, 190-191

- Brilliant cresyl blue test, in
hemoglobinopathies, 810
- Broad casts, in urine, 18
- Bronchopulmonary dysplasia, treatment of,
electrolyte imbalance in, 391
- Buffer(s), in acid-base regulation, 104-105
- Buffer loading tests, in renal tubular
acidosis, 124-126
- Buffy coat, erythrocyte sedimentation rate
and, 788-789
- BUN (blood urea nitrogen), 44
in elderly persons, 269-270
- Burns, lymphocytopenia in, 929
- Calciferol, in metabolic disease, 428
- Calcification, metastatic, in
hyperphosphatemia, 190
- Calcinosis, tumoral, hyperphosphatemia in,
189
- Calciphylaxis, systemic, in
hyperphosphatemia, 190
- Calcitonin, in hypercalcemia, 176
- Calcium, determination of, in hypertension,
290
imbalance of, 157-181. See also *Hypercal-
cemia*; *Hypocalcemia*.
tests for, 158-160
vs. normal calcium balance, 157-158
in geriatric nutrition, 442-443
in neonatal nutrition, 394-395
- Calcium chloride loading test, in renal
tubular acidosis, 122
- Calcium ethylenediaminetetraacetic acid, in
lead toxicity, 247
- Calcium gluconate, in hypocalcemia, 167
- Calcium oxalate, in urine, 18
- Cancer, disseminated intravascular
coagulation in, 955
free radicals in, 472-475
hypercalcemia in, 172-173
hyperphosphatemia in, 187-188
lymphocytopenia in, 930
neutrophilia in, 871
thyroid, 725-738
classification of, 726-727
computed tomography of, 721-722
diagnosis of, 727-729
differentiated, thyroglobulin measure-
ments in, 731-732
epidemiology of, 725
magnetic resonance imaging of, 723
prognosis for, 729-730
recurrent, monitoring for, 732-733
treatment of, 729-732
ultrasonography of, 718
- Captopril test, in renovascular
hypertension, 299
- Carbohydrates, hypophosphatemia from,
197-198
in neonatal nutrition, 393-394
thyroid hormone action and, 552-553
- Carbon dioxide, in acid-base balance, 104-
105
partial pressure of, with phosphate infu-
sion, in renal tubular acidosis, 126
with urinary alkalinization, in renal
tubular acidosis, 125-126
- Carboxylase deficiency, nutrition support
in, 429-430
- Cardiopulmonary bypass,
lymphocytopenia in, 929
- Cardiovascular disease, lymphocytopenia
in, 929
- Carnitine, deficiency of, in neonates, 393
in metabolic disease, 430
- Carotenoids, as antioxidants, 470-471, 474-
475
- Cartilage-hair syndrome, lymphocytopenia
in, 926
- Casts, in urine, 17-18
in kidney failure, 93
- Catabolic flow phase, in severe illness, 366
- Catalase, as free radical scavenger, 469
- Catecholamines, excess of, in hypertension,
295-297
- Cationic dyes, 761
- Cause and effect diagram, in quality
management, 522
- Cell counters, in hematology. See
Instrumentation, hematology.
- Cell cycle analysis, flow cytometry in, 842,
844
- Cell hemoglobin concentration mean, 776,
780
- Cellular casts, in urine, 17
- Cellular immunodeficiency with
immunoglobulins syndrome, 926
- Ceruloplasmin, as antioxidant, 470
determination of, 383
in infants, 398
- CH50 assay, for complement, 76
- CHCM (cell hemoglobin concentration
mean), 776, 780
- Check sheets, in quality management, 522
- Chediak-Higashi syndrome, neutropenia
in, 882-884
- Chemotherapy, hyperphosphatemia in,
187-188
lymphocytopenia in, 927
- Chenzinsky stains, 760-762
- 4-Chloronaphthol, in myeloperoxidase
detection, 913-914
- Chlorpropamide, in diabetes insipidus, 147
- Cholecalciferol, in neonatal nutrition, 400
- Cholesterol, determination of, in
hypertension, 290-291

- in wellness testing, 487-489
- in elderly persons, 438
- Christmas disease, 955
- Chromatography, column, in hemoglobin quantitation, 808
- in prostaglandin determination, 244-245
- liquid, in ascorbic acid assay, 378-379
- in free radical measurement, 471-472
- in retinol assay, 380
- in tocopherol assay, 380
- in vitamin B₆ assay, 376
- Chromium, determination of, in nutritional assessment, 384
- in neonatal nutrition, 398-399
- Chromium-51 ethylenediaminetetraacetic acid, in kidney function assessment, 56
- Chromogens, noncreatinine, 39-41
- Chronic idiopathic neutropenia, 885
- Chronic lymphocytic leukemias, diagnosis of, flow cytometry in, 840-841
- Chronic myeloid leukemia, vs. reactive neutrophilia, 873-874
- Chronic neutrophilic leukemia, vs. reactive neutrophilia, 874
- Chylothorax, lymphocytopenia in, 929
- Circumference, of body parts, in nutritional assessment, 334
- Cirrhosis, Indian childhood, 398
- Clearance, in kidney, 5
 - creatinine. *See Creatinine clearance.*
 - inulin, 34, 36-38, 54-55
 - iodohippurate, 45
 - para-aminohippurate, 34-38, 272
 - radioactive iothalamate, 44-45
- Clinical Laboratory Act of 1988, proficiency testing regulations of, 973-974
- Clinical Laboratory Improvement Amendments of 1988. *See under Regulatory and legislative issues.*
- Clinical pathology, definition of, 516-517
- Clonidine test, in pheochromocytoma, 297
- Clotting function tests, in vitamin K assay, 381
- Coagulation disorders. *See Hemostasis, disorders of.*
- Cobalt, requirements of, in elderly persons, 444-445
- Cofactor-replacement therapy, in metabolic diseases, 427-430
- Colloid nodule, fine-needle aspiration in, 701
- Colony-stimulating factor, in neutropenia, 892
- Colorimetry, in ascorbic acid assay, 378-379
 - in copper determination, 383
 - in zinc determination, 382
- Compartmental analysis, with radioisotopes, in kidney function assessment, 57
- Complement system, activation of, markers for, 77
 - determination of, in glomerular disease, 76-77
 - evaluation of, in nutritional assessment, 461
- Complement-specific immune complex procedure, 73
- Complete blood count, enhancement of, red cell indices in, 781-782
 - in hemoglobinopathies, 809
 - in hypertension, 288
- Computed tomography, in nutritional assessment, 336
 - of thyroid gland, 719-722
- Computers, in quality management, 521
- Concanavalin A, in lymphocyte function testing, 341
- Concentration, urinary, 131-134
 - in elderly persons, 274-275
 - in pediatric patients, 260
- Conductivity, total body, in nutritional assessment, 337
- Conglutinin assay, for immune complexes, 72
- Control charts, in quality management, 523
- Copper, as antioxidant, 470
 - determination of, in nutritional assessment, 382-383
 - in geriatric nutrition, 445
 - in neonatal nutrition, 397-398
- Coronary artery disease, lipoprotein oxidation in, 472-475
- Corticosteroids, lymphocytopenia from, 928-929
- Cortisol, excess of, in hypertension, 294-295
- COUP-TF, thyroid hormone receptor auxiliary proteins and, 534-535
 - transcription factor reactions with, 536
- C1q binding assay, for immune complexes, 71-72
- C-reactive protein, in nutritional assessment, 366
- Creatinine, determination of, 40-41
 - in hypertension, 289-290
 - in nutritional assessment, 335
- Creatinine clearance, 35-44
 - in elderly persons, 270-272
 - in hypertension, 289-290
 - in pediatric patients, 258-259
 - in renal disease, 41-44
 - vs. glomerular filtration rate, 42-43, 55
- O-Cresolphthalein, in calcium determination, 158
- Cribriform kinetoplast staining, in DNA antibody measurement, 74
- Crohn's disease, hypocalcemia in, 164
 - lymphocytopenia in, 928

- Crystals, in urine sediment, 18
- Cyanocobalamin (vitamin BCC12DD), in
geriatric nutrition, 446-447
in metabolic disease, 427-428
in neonatal nutrition, 377, 404
- Cycle times, in laboratory testing, 520-521
- Cyclic neutropenia, 882-883
- Cytochemistry, stains for. *See Stains.*
- Cytochrome c oxidase, measurement of, in
nutritional assessment, 383
- Cytokines, in neutropenia, 892
lymphocytopenia from, 928
- Cytology, fine-needle. *See Fine-needle
aspiration.*
proficiency testing in, 992
- Cytomegalovirus infections, lymphocytosis
in, 867
- Cytometry. *See Flow cytometry.*
- Cytopenia, multilineage, neutropenia in,
885, 888
- Cytosolic thyroid hormone binding
proteins, 537-538
- Data collection tools, in quality
management, 522-523
- D-Dimer assay, 953
in disseminated intravascular coagula-
tion, 958
- Deamino-8-D-arginine vasopressin
(DDAVP), in kidney function
assessment, 123
- Death, predictive models for, 346-347
- Dehydration, in neonates, 391
- Dehydration test, for kidney concentrating
capacity, 133-134
- Delayed hypersensitivity, in nutritional
assessment, 340-341, 345-346, 461
- Dendritic cells, in autoimmune thyroid
disease, 690-694
- Deoxyuridine suppression test, in folic acid
assay, 377
- Department of Health and Human
Services, laboratory regulations of, 741
- Depression, transthyretin levels in, 591
- Desmopressin acetate, in diabetes
insipidus, 147
- Detoxification, in inborn metabolic disease,
430
- Diabetes insipidus, 144, 146-147
- Diabetes mellitus, nutrition support in, 413
- Diabetic ketoacidosis, thyroxine-binding
globulin levels in, 589
- Dialysis, methods using, in free thyroxine
measurement, 613-615, 654-656, 663-
667
renal, aluminum bone disease in, hyper-
calcemia in, 171
- hypophosphatemia in, 196
in hyperkalemia, 152
- Diesse System, for erythrocyte
sedimentation rate, 792
- Diet, creatinine levels and, 40
for metabolic diseases, 430-432
for nephrolithiasis, 232
for phenylketonuria, 419-422
hyperphosphatemia from, 186-187
hypophosphatemia from, 198-199
renal function and, 37
- Dihydrobiopterin, determination of, in
phenylketonuria, 418
- 1 α ,25-Dihydroxyvitamin D assay, 381
- Dilution, urinary, 131-134
in elderly persons, 275
inadequate, hyponatremia in, 137-138
- Dilutional hyponatremia, 138
- Dinitrophenylhydrazine test, in vitamin C
assay, 379
- Diphenylhydantoin, hypocalcemia from,
165
- 2,3-Diphosphoglycerate, reduced synthesis
of, in hypophosphatemia, 202-203
- Diphosphonates, in hypercalcemia, 176
in hyperphosphatemia, 189
- Direct immunofluorescence assay, for
glomerular basement antibody, 78
- Disaccharidase deficiency, nutrition
support in, 423
- Disseminated intravascular coagulation,
956-959
- Diuretics, electrolyte imbalance from, 391
hypercalcemia from, 174
hypophosphatemia from, 195
in hypercalcemia, 176
in nephrolithiasis, 232
- Diurnal rhythm, of renal function, 37
- DNA, analysis of, in hemoglobinopathies,
811
determination of, flow cytometry in, 842,
844
thyroid hormone receptor interactions
with, 533-535
- DNA antibody measurement, in
glomerular disease, 73-75
- Down syndrome, transient
myeloproliferative disorder in, 874-
875
- Drug(s), effects of, on transthyretin levels,
591
thyroxine-binding globulin levels, 589
hypocalcemia from, 166
interactions with nutrients, 325
kidney injury from, in pediatric patients,
263-264
lupus anticoagulant from, 962
lymphocytosis from, 867
neutropenia from, 882, 884-885

- neutrophilia from, 871
- Dual photon absorptiometry, in nutritional assessment, 336
- Dyes. *See Stains.*
- Dysfibrinogenemia, in liver disease, 959
- Ebb phase, in severe illness, 366
- Edema, brain, in hyponatremia, 141-142
 - from infant formulas, 393
- Education, for quality management, 518-519
- Effective renal plasma flow, 6
 - calculation of, 35
 - measurement of, in elderly persons, 272-274
 - radioisotopes in, 61-64
- Ektadem slide method, in calcium determination, 158
- Elderly persons, kidney function in,
 - assessment of, 269-277
 - nutrition in, 435-455
 - assessment of, 325, 348, 436-438
 - energy requirements, 438-441
 - mineral requirements in, 442-445
 - physiology changes and, 435-436
 - protein requirements, 441-442
 - psychological changes and, 436
 - socioeconomic changes and, 436
 - vitamins in, 445-451
- Electrolyte balance, in neonates, 390-391
- Electron spin resonance, in free radical measurement, 471
- Electrophoresis, hemoglobin, 803-808
 - acid, 804
 - alkaline, 803-804
 - globin chain, 804
 - isoelectric focusing, 804, 806
 - quantitative, 806, 808
 - protein, in immune complex measurement, 70
- ELISA. *See Enzyme-linked immunosorbent assay.*
- Endothelium-derived relaxing factor, 467
- Enema, phosphorus-containing,
 - hyperphosphatemia in, 185-186
- Energy requirements, for elderly persons, 438-441
- Enteral nutrition, 500
- Enzyme(s), renal, in urine, 15
- Enzyme immunoassay, for prostatic acid phosphatase, 282
- Enzyme-linked immunoassay, for immune complexes, 73
- Enzyme-linked immunosorbent assay, for
 - DNA antibodies, 74-75
 - for kallikrein-kinin system activity, 240-241
- Eosin stains, 761-765, 767-768
- Eosinophils, in urine, 16-17
- Epilepsy, thyrotropin measurements in, 678-679
- Epinephrine, excess of, in hypertension, 295-297
 - hypophosphatemia from, 198
- Epstein-Barr virus infection, lymphocytosis in, 864-866
- Ergocalciferol, in neonatal nutrition, 400
- Erythrocyte(s), abnormal, in
 - hypophosphatemia, 202-203
 - flow cytometry studies of, 847
 - in urine sediment, 16
 - morphology of, in hemoglobinopathies, 809
- Erythrocyte enzyme activity tests, in vitamin assay, 376
- Erythrocyte fragility test, in vitamin E assay, 380-381
- Erythrocyte glutathione reductase test, in vitamin assay, 375
- Erythrocyte indices. *See Red cell indices.*
- Erythrocyte sedimentation rate, 787-800
 - automation of, 792-793
 - background of, 788-791
 - buffy coat formation and, 788-789
 - closed systems for, 792-793
 - disposable tubes for, 791-792
 - methodology for, 791-793
 - performance characteristics of, 792
 - quality control programs for, 793
 - reference range for, 788
 - usefulness of, 794-796
- Erythrocyte superoxide dismutase,
 - measurement of, in nutritional assessment, 383
- Erythrocyte transketolase stimulation test, in vitamin assay, 375
- Erythroid disorders, diagnosis of, flow cytometry studies in, 847
- Erythropoietin, synthesis of, in kidney, 10
- Erythro-5,6,7,8-tetrahydrobiopterin loading test, in phenylketonuria, 418
- Essential fatty acids, deficiency of, in neonates, 392-393
- Estrogens, hypophosphatemia from, 198
 - therapy with, thyroxine-binding globulin levels in, 588
- Ethane hydroxydiphosphonate, in hypercalcemia, 176
- Euvolemic hyponatremia, 144
- Euvolemic hyponatremia, 137-138, 142
- Exercise, mean platelet volume in, 944
- External imaging methods, in kidney function assessment, 60-61, 63-64
- Factor VIII, antibodies to, 961-962

- Factor VIII (*Continued*)
 deficiency of, 954-955
- Factor XII deficiency, 964
- Failure to thrive, in neonates, 391
- Familial dysalbuminemic hyperthyroxinemia, 591-592
- Familial hyperkalemic periodic paralysis, 152
- Familial hypocalciuric hypercalcemia, 171
- Familial hypophosphatemic rickets, 400-401
- Fanconi syndrome, hypophosphatemia in, 194
- Fanconi's anemia, neutropenia in, 882-883
- Farr radioimmunoassay, for DNA antibodies, 74
- Fat(s), in neonatal nutrition, 392-393
 malabsorption of, hypocalcemia in, 164
 in neonates, 393
 metabolic disorders of, nutrition support in, 416
- Fatty acids, essential, deficiency of, in neonates, 392-393
- Fechtnr syndrome, mean platelet volume in, 945
- Felty's syndrome, lymphocytopenia in, 930
- Ferritin, determination of, in wellness testing, 486-487
- Fetal hemoglobin, detection of, 809-811
 acid elution for, 910-912
 persistence of, 803
 quantitation of, 808
- Fetal-maternal hemorrhage, detection of, flow cytometry in, 847
- Fever, band count in, 898
- Fibronectin, in nutritional assessment, 339-340, 364-365
- Filtration fraction, 6
 calculation of, 36
- Financial implications, of malnutrition, 493-509
- Fine-needle aspiration, of thyroid, 699-709
 in cancer diagnosis, 728-729
 ultrasonographic guidance of, 716-719
- Flagging systems, for hematology instruments, 824-825
- Flow charts, in quality management, 522
- Flow cytometry, 831-852
 advantages of, 835-836
 applications of, 835
 data presentation in, 835
 in cell cycle analysis, 842, 844
 in DNA content determination, 842, 844
 in erythrocyte studies, 847
 in granulocyte assay, 845-846
 in human immunodeficiency virus infection monitoring, 844-845
 in immunologic monitoring, 844-845
 in lymphoproliferative disorder diagnosis, 838-842
 acute lymphocytic leukemia, 838-840
 acute mixed lineage leukemias, 840
 chronic lymphocytic leukemias, 840-841
 lymphoma, 841-842
 in monocyte assay, 845-846
 in multiple myeloma diagnosis, 842
 in plasma cell dyscrasia diagnosis, 842
 in platelet studies, 846
 instrument components for, 832
 monoclonal antibodies in, 836-838
 overview of, 831-836
 quality control in, 847-848
 stains for, 832-833
- Fludrocortisone, in hyperkalemia, 152
- Fluid balance, in neonates, 390-391
- Fluid intake, in nephrolithiasis, 232
- Fluorescent dyes, for flow cytometry, 832-833
 in magnesium determination, 216-217
- Fluoride requirements, in elderly persons, 445
- Folic acid, assay for, 376-377
 in geriatric nutrition, 446-447
 in neonatal nutrition, 404
- Folin-Wu reaction, in creatinine determination, 40-41
- Follicular thyroid carcinoma, 726, 730
- Follicular thyroid neoplasia, fine-needle aspiration in, 701-702
- Food and Drug Administration, laboratory regulations of, 741
- Fractional excretion of filtered sodium test, in kidney failure, 94-97
- Free radicals, antioxidants for, 468
 cancer and, 474-475
 in atherogenesis, 478-480
 transition metals as, 469-470
 vitamins as, 470-471
 definition of, 465-466
 enzymes for scavenging of, 468-469
 in atherogenesis, 475-480
 in carcinogenesis, 472-475
 measurement of, 471-472
 sources of, 465-467
- Free thyroxine. *See under Thyroxine.*
- Fructose, hypophosphatemia from, 198
- Fructose intolerance, nutrition support in, 423
- Furosemide, in hyperkalemia, 152
- Furosemide test, in renal tubular acidosis, 124
- Galactitol, determination of, 425
- Galactose, in fruits and vegetables, 426

- Galactosemia, nutrition support in, 422-427
 pathophysiology of, 412, 417
- Gamma camera, in glomerular filtration rate determination, 60-61, 63-64
- Gates method, for glomerular filtration rate determination, 60
- Gene expression, thyroid hormone receptors in, 535-536
- Gene transcription, thyroid hormone receptors in, 536
- Giemsa stains, 765-766, 906-907
- Globin chain electrophoresis, hemoglobin, 804
- Globin chain synthesis ratios, in hemoglobinopathies, 810
- Glomerular basement antibody disease, serologic evaluation in, 78-79
- Glomerular disease, serologic evaluation of, 69-87
 antineutrophil cytoplasmic antibodies in, 79-81
 complement determination in, 76-77
 DNA antibody measurements in, 73-75
 glomerular basement antibody disease, 78-79
 immune complex measurements in, 70-73
 membranoproliferative glomerulonephritis, 77
 postinfectious glomerulonephritis, 81-82
- Glomerular filtration rate, clearance and, 5
 decreased, hyperphosphatemia in, 184-186
 estimation of, clearance in, 34-38, 53-55
 creatinine measurements in, 39-44
 in elderly persons, 269-272
 in pediatric patients, 257-259
 radioisotopes in, 44-45, 55-61
 renal plasma flow in, 33-36
 urea measurement in, 44
 in kidney failure, 97-98
 lead effects on, 245-246
 normal, 37
 regulation of, 3-5
 variations in, 37-38
 vs. creatinine clearance, 42-43
 vs. plasma creatinine, 42-43
- Glomerulitis, with vasculitis, diagnosis of, 92
- Glomerulonephritis, crescentic, serologic evaluation of, 78-79
 in hepatitis B, 82
 membranoproliferative, serologic evaluation in, 77
 postinfectious, serologic evaluation in, 81-82
- Glomerulus, anatomy of, 3
 permeability of, in elderly persons, 276
- Glucagon, hypophosphatemia from, 198
- Glucagon provocation test, in pheochromocytoma, 297
- Glucose, determination of, in hypertension, 290
 hypophosphatemia from, 201-202
 in hyperkalemia, 152
 tubular reabsorption of, 47-48
- Glutathione peroxidase, as free radical scavenger, 469
 measurement of, in selenium deficiency, 398
- Glycogen storage disease, nutrition support in, 413, 431
- Goiter, in thyroid hormone resistance, 566-567
 intrathoracic, computed tomography of, 720
 magnetic resonance imaging of, 723
 simple, 690
- Goodpasture's syndrome, serologic evaluation in, 78-79
- Granular casts, in urine, 17-18
- Granulocyte(s), assay of, flow cytometry in, 845-846
 defects of, neutropenia in, 881-882
- Granulocyte colony-stimulating factor, in neutropenia, 892
- Granulocytopoiesis, 870
- Granulomatosis, hypercalcemia in, 173-174
 Wegener's, antineutrophil cytoplasmic antibodies in, 79-81
- Graves' disease, autoantibodies in, 687-689
 ophthalmopathy in, computed tomography of, 721
 ultrasonography of, 718
- Grünwald stains, 764-765
- Hairy cell leukemia, diagnosis of, flow cytometry in, 841
 stains for, 918-919
- Harvey hospital prognostic index, in nutritional assessment, 346
- Hashimoto's thyroiditis, autoantibodies in, 689-690
 fine-needle aspiration in, 701
- Health Care Financing Administration, laboratory regulations of, 740-741, 985-986
- Heinz body preparation, 912-913
- Hematocrit, instruments for, 822
 Zeta, 792
- Hematologic testing, 759-994
 band count, 895-903
 cell counting, 817-829
 cytochemistry, 905-921
 erythrocyte sedimentation rate, 782-800

- Hematologic testing (*Continued*)
 flow cytometry in, 831-852
 in hemoglobinopathies, 801-816
 in hemostasis, 951-971
 in lymphocytopenia, 923-934
 in neutropenia, 879-893
 in reactive lymphocytosis, 863-870
 in reactive neutrophilia, 850-875
 instrumentation for, 817-829
 mean platelet volume, 937-950
 peripheral smear in, 853-861
 proficiency testing in, 973-985
 red cell indices, 773-785
 stains in, 759-771
- Hematopoietic system, flow cytometry studies of, 836-838
- Hematuria, 16
- Hemochromatosis, perinatal, 396
- Hemodialysis, in hyperkalemia, 152
- Hemoglobin, composition of, 802-803
 fetal, detection of, 809-811
 acid elution for, 910-912
 persistence of, 803
 quantitation of, 808
 solubility tests for, in hemoglobinopathies, 809
 unstable, detection of, 809
 variant forms of, 802-803
- Hemoglobin distribution width, 776
- Hemoglobin S, detection of, 803-804, 806, 808-809, 811
- Hemoglobinopathies, diagnosis of, 801-816
 brilliant cresyl blue test for inclusion bodies, 810
 complete blood count in, 809
 DNA analysis in, 811
 electrophoresis in, 803-808
 globin chain synthesis ratios in, 810
 hemoglobin composition and, 802-803
 hemoglobin quantitation in, 806, 808
 hemoglobin solubility tests in, 809
 Kleihauer-Betke stain for, 810
 methods for, 803
 monoclonal antibody tests in, 809
 recommendations for community hospital laboratory, 811-813
 red cell morphology in, 809
 reference laboratory tests in, 810-811
 unstable hemoglobin screen in, 809
- Hemolytic anemia, diagnosis of, staining for, 912-913
 from infant formulas, 393
- Hemophilia, lymphocytopenia in, 930
- Hemophilia A, 954-955
- Hemophilia B, 955
- Hemorrhage, fetal-maternal, detection of, flow cytometry in, 847
 in disseminated intravascular coagulation, 956-959
 in liver disease, 960-961
- Hemostasis, 951-971
 disorders of, acquired circulating anticoagulants, 961-963
 congenital coagulation defects, 954-956
 disseminated intravascular coagulation, 956-959
 hypercoagulability, 964-967
 in liver disease, 959-961
 elements of, 952-954
- Henderson equation, 106-107
- Henderson-Hasselbalch equation, 105
- Hepatitis, retinol-binding protein levels in, 362
- Hepatitis B, glomerulonephritis in, 82
- Heterophil antibody test, in infectious mononucleosis, 865-866
- High-dose hook effect, in thyrotropin assay, 676-677
- Hip circumference, in nutritional assessment, 334
- Histograms, in quality management, 522
- HIV infection. *See Human immunodeficiency virus infection.*
- Hodgkin's disease, erythrocyte sedimentation rate in, 795
 hypercalcemia in, 172
 lymphocytopenia in, 929
- Hormones, thyroid. *See Thyroid hormone(s).*
- Hospital, length of stay, predictive models for, 346-348
- Hospital prognostic index, in nutritional assessment, 346
- Human herpes virus-6 infection, lymphocytosis in, 867
- Human immunodeficiency virus infection, acute, lymphocytosis in, 867
 flow cytometry studies in, 844-845
 hypocalcemia in, 166
 lymphocytopenia in, 926
 mean platelet volume in, 944
 thyroxine-binding globulin levels in, 589
- Human milk, nutrition and, 390-392, 394-397, 403-404
- Hungry bone syndrome, hypocalcemia in, 165
 hypophosphatemia in, 199
- Hürthle cell cancer, 726
- Hürthle cell neoplasms, fine-needle aspiration in, 702
- Hyaline casts, in urine, 17
- Hydrogen ion, conversion to pH, 107-108
 excretion of, in elderly persons, 275
- Hydrogen peroxide, formation of, from free radical reactions, 466
- Hydroxyl radical, as oxidant, 466-467
- 11-Hydroxylase deficiency, hypertension in, 299-300

- 17 α -Hydroxylase deficiency, hypertension in, 299-300
- 25-Hydroxyvitamin D assay, 381
- Hyperalbuminemia, hypercalcemia in, 168
- Hypercalcemia, 168-177
- causes of, 168
 - differential diagnosis of, 168-175
 - familial hypocalciuric, 171
 - humoral, 172-173
 - hypophosphatemia with, 193
 - iatrogenic, 174
 - malignancy-associated, 172-173
 - of infancy, 174-175
- Hypercalciuria, absorptive, in kidney stone formation, 230
- Hyperchloremic metabolic acidosis, 109-110, 112-113
- Hypercholesterolemia, wellness testing for, 487-489
- Hypercoagulability states, 964-967
- Hyperkalemia, 149-153
- causes of, 149-152
 - familial periodic paralysis in, 152
 - in hypokalemia therapy, 155
 - pseudo-, 149
 - treatment of, 152-153
- Hyperlipidemia, pseudohyponatremia in, 137
- Hyernatremia, 142-147
- assessment of, 146
 - etiology of, 142, 144
 - euvolemic, 144
 - hypervolemic, 144
 - hypovolemic, 144
 - in neonates, 391
 - symptoms of, 144, 146
 - treatment of, 146-147
- Hyperparathyroidism, hypercalcemia in, 168-172
- hypocalcemia in, 163-166
 - hypophosphatemia in, 193-195
 - primary, 168-170
 - secondary, 170
 - tertiary, 170-171
- Hyperphenylalaninemia. See *Phenylketonuria*.
- Hyperphosphatemia, 184-192
- consequences of, 189-191
 - differential diagnosis of, 184-189
 - hypocalcemia in, 165-166
 - in infants, 188
 - treatment of, 191-192
- Hyperproteinemia, pseudohyponatremia in, 137
- Hypersensitivity, delayed, in nutritional assessment, 340-341, 345-346, 461
- Hypersplenism, neutropenia in, 884, 888
- Hypertension, 287-302
- blood tests in, 288-291
 - in adrenal disorders, 292-297
 - in renal disorders, 297-299
 - kallikrein-kinin system in, 240
 - lead burden and, 245-247
 - prostaglandins in, 243-244
 - renovascular, 297-299
 - unusual causes of, 299-300
 - urine tests in, 291
- Hyperthermia, therapeutic, hypophosphatemia in, 195-196
- Hyperthyroidism, free thyroxine levels in, 658-660
- hypercalcemia in, 173
 - thyrotropin measurements in, 679-681
 - thyroxine-binding globulin levels in, 588
- Hyperventilation, hypophosphatemia in, 196-197
- Hypervolemic hyernatremia, 144
- Hypervolemic hyponatremia, 138
- Hypoalbuminemia, 339, 356-357, 591-592
- hypocalcemia in, 161
- Hypocalcemia, 160-168
- causes of, 160
 - clinical features of, 166-167
 - differential diagnosis of, 161-166
 - hyperphosphatemia and, 188, 190
 - neonatal, 166
 - treatment of, 167-168
- Hypocalciuric hypercalcemia, familial, 171
- Hypocomplementemia, in glomerular disease, 76-77
- Hypofibrinogenemia, in disseminated intravascular coagulation, 955
- Hypoglycemia, nutrition support in, 413
- Hypokalemia, 153-155
- causes of, 153-154
 - in hypertension, 293-294
 - treatment of, 154-155
- Hypomagnesemia, hypocalcemia in, 162-163
- hypophosphatemia with, 196
- Hyponatremia, 136-142
- acute, 138-139
 - after prostatectomy, 139
 - assessment of, 140
 - clinical presentation of, 136-137
 - dilutional, 138
 - euvolemic, 137-138, 142
 - hypervolemic, 138
 - hypovolemic, 137-138, 142
 - in neonates, 391
 - in oxytocin therapy, 139
 - in preterm infants, 261
 - pathophysiology of, 137-139
 - postoperative, 139
 - progressive, 138
 - pseudo-, 137
 - symptoms of, 139-140
 - treatment of, 140-142

- Hypoparathyroidism, hyperphosphatemia in, 188
 hypocalcemia in, 161-163
- Hypophosphatemia, **192-204**
 acute, 203
 congenital X-linked, 194
 consequences of, 200-203
 differential diagnosis of, 192-199
 fructose-induced, 198
 hypercalcemia with, 193
 phosphate therapy for, hyperphosphatemia in, 187
 profound, 200-201
 redistribution, 196-199
 renal, 194-196
 rickets in, 400-401
 treatment of, 203-204
- Hypothyroidism, congenital, **645-652**
 biochemical features of, 650
 clinical features of, 649
 epidemiology of, 648
 etiology of, 648-649
 prognosis for, 650-651
 screening methodology for, 646-648
 treatment of, 650
 free thyroxine levels in, 658-660
 mean platelet volume in, 946
 thyrotropin measurements in, 679-681
 thyroxine-binding globulin levels in, 588
- Hypotransferrinemia, 358
- Hypovolemic hypernatremia, 144
- Hypovolemic hyponatremia, 137-138, 142
- Idiogenic osmoles, 141-142
- Imaging, in kidney failure, 97, 99
 of thyroid gland. *See under Thyroid gland.*
- Immobilization, hypercalcemia in, 174
- Immune complexes, anti-DNA antibodies in, 73-75
 complement activation by, 76-77
 in glomerulonephritis, 77, 81-82
 measurement of, in glomerular disease, 70-73
- Immune function, flow cytometry studies of, 836-838
 nutrition and, **457-463**
 assessment in, 340-341, 460-462
 in nutritional deficiency, 458-460
- Immunoassay, for free thyroxine, Sephadex absorption method for, 624-625
 single-step approach to, 617-624
 analogue protein binding in, 620-622
 labeled analogue methods in, 618-620
- labeled antibody methods for, 622-624
 two-step direct approach to, 615-617
- for thyroid function testing, automation of, **631-644**
 competitive, 633
 data management for, 633-634
 disadvantages of, 635
 heterogenous, 632-633
 homogenous, 632-633
 immunometric, 633
 performance of, 638-643
 reagent stability in, 633
 sample management in, 634
 signal detection in, 634-635
 systems for, 635-638
- Immunoblasts, in reactive lymphocytosis, 869
- Immunocytochemical stains, 919
- Immunodeficiency, flow cytometry studies in, 844-845
 lymphocytopenia in, 925-926
- Immunoglobulin(s), light chains of, in urine, 15-16
- Immunoglobulin G, thyrotropin-binding, 687
- Immunohistochemistry, of prostatic acid phosphatase, 284
- Immunologic evaluation, flow cytometry in, 844-845
- Immunoradiometric assay, for thyroxine-binding globulin, 594
- Indian childhood cirrhosis, 398
- Indirect immunofluorescence assay, for antineutrophil cytoplasmic antibodies, 79-81
 for glomerular basement antibody, 78
- Infants, newborn. *See Neonates.*
- Infections, erythrocyte sedimentation rate in, 795-796
 neutropenia in, 884-885
 neutrophilia in, 870-871
 reactive lymphocytosis in, 864
- Infectious mononucleosis, 864-866
 diagnosis of, 864-866
 lymphocyte morphology in, 864
 symptoms of, 864
- Inflammation, transthyretin levels in, 591
- Inflammatory bowel disease, lymphocytopenia in, 928
- Influenza, lymphocytopenia in, 930
- Infrared intertactance, in nutritional assessment, 336
- Infrared spectroscopy, in kidney stone analysis, 230
- Instrumentation, hematology, **817-829**
 for centralized laboratories, 820-821
 for intensive care units, 822
 for outpatient clinics, 822-823

- for reticulocyte counting, 823-824
- for satellite laboratories, 821-824
- performance of, 819-820
- regulatory concerns in, 818-819
- selection of, 824-828
- Insulin, hypophosphatemia from, 198
- in hyperkalemia, 152
- Insulin growth factor 1 (somatomedin C),
 - in nutritional assessment, 362-364
- Interleukins, in neutropenia, 892
- in nutritional assessment, 366-367
- Interstate Quarantine Regulations, for
 - specimen shipping, 742
- Inulin clearance, 5, 34, 36-38, 54-55
- Iodine, deficiency of, major
 - histocompatibility complex antigens and, 692-694
 - requirements of, in elderly persons, 444
- Iodine radioisotopes, in thyroid imaging,
 - 711, 713-714
- Iododiatrizoate, labeled, in kidney function
 - assessment, 55
- Iodhippurate, labeled, in kidney function
 - assessment, 45
- Ion-selective electrodes, in calcium
 - determination, 159
- Iothalamate, labeled, in kidney function
 - assessment, 44-45, 55-56
- Iron, as oxidant, 469
 - in geriatric nutrition, 443-444
 - in neonatal nutrition, 395-396
 - stains for, 908-910
 - transferrin binding to, 357-358
- Iron deficiency anemia, 443-444
 - red cell indices in, 777-781
 - wellness testing for, 486-487
- Islet cell tumors, hypercalcemia in, 173
- Isoelectric focusing electrophoresis,
 - hemoglobin, 804, 806
- Isopropanol precipitation test, in
 - hemoglobinopathies, 809
- Isotope studies, in nutritional assessment,
 - 335
- Jaffe reaction, in creatinine determination,
 - 40-41
- Jenner stains, 764-765
- Joint Commission for Accreditation of
 - Healthcare Organizations,
 - requirements of, 740
- Kallikrein-kinin system, in kidney function,
 - 9, 235-241
- Kappa:lambda test, in lymphoma, 841
- Kayexalate, in hyperkalemia, 152
- Ketoacidosis, diabetic, thyroxine-binding
 - globulin levels in, 589
- Kety-Renkin-Crone equation, 604-605
- Kidney, anatomy of, 1-8
 - biopsy of, 30, 97
 - blood flow of, 6
 - in elderly persons, 273-274
 - blood supply of, 2-4
 - enzymes of, in urine, 15
 - failure of. *See Kidney failure.*
 - function of. *See Kidney function.*
 - injury of, in pediatric patients, 262-264
 - parenchymal disease of, hypertension in,
 - 299
 - stones in. *See Nephrolithiasis.*
 - transplantation of, hypophosphatemia
 - after, 194
 - tubules of, anatomy of, 6-8
 - function of, 6-8
 - assessment of, 46-48, 259-260, 274-275
 - necrosis of, 91-92
 - phosphate reabsorption in, 188-189,
 - 194-195
 - potassium secretion in, 150
 - urine acidification in. *See Renal tubular acidosis.*
 - vascular disease of, hypertension in, 297-299
 - Kidney failure, chronic, creatinine in, 41-42
 - diagnosis of, 89-102
 - acute, 89-97
 - biopsy in, 97
 - chronic, 97-100
 - imaging in, 97, 99
 - laboratory procedures in, 93-97, 99
 - parenchymal, 91-92
 - physical examination in, 92-93
 - postrenal, 91
 - prerenal, 89-91
 - hypercalcemia in, 177
 - hyperkalemia in, 149-150
 - hyperphosphatemia in, 184-186, 190-191
 - hypocalcemia in, 163
 - mean platelet volume in, 944-945
 - recovery from, hypercalcemia in, 171
 - retinol-binding protein levels in, 361
 - thyroxine-binding globulin levels in, 588
 - Kidney function. *See also Glomerular filtration rate; Urine.*
 - assessment of, antineutrophil cytoplasmic antibodies in, 79-81
 - blood urea nitrogen in, 44, 269-270
 - complement determination in, 76-77
 - concentrating ability, 131-134
 - diluting ability, 131-134
 - DNA antibody measurements in, 73-75
 - glomerular, 33-46

Kidney function (*Continued*)

- immune complex measurements in, 70-73
- in elderly persons, 269-277
- in glomerular basement antibody disease, 78-79
- in membranoproliferative glomerulonephritis, 77
- in pediatric patients, 257-267
- in postinfectious glomerulonephritis, 81-82
- in renal tubular acidosis, 117-129
- radioisotope methods in, 44-45, 53-68
- serologic methods in, 69-87
- tubular, 46-48, 259-260, 274-275
- urinalysis in. See *Urinalysis*.
- urinary sediment analysis in, 16-18, 93-94
- clearance in. See *Clearance*.
- electrolyte imbalance and, calcium, 157-181
 - magnesium, 209-223
 - phosphate, 183-207
 - potassium, 149-156
 - sodium, 135-148
- hypercalcemia effects on, 175-176
- hypertension and, 297-299
- in acid-base regulation, 105, 108
- in diabetes insipidus, 144
- in hypertension, 291
- in potassium balance, 149, 261-262
- kallikrein-kinin system in, 9, 235-241
- lead effects on, 245-248
- leukotrienes in, 241-244
- prostaglandins in, 241-245
- regulation of, 8-10
- thromboxanes in, 241-244
- tubular, 6, 8
 - assessment of, 46-48
 - function of, 259-260
 - variations in, 37-38
- Kinin(s), in kidney function, 239-240
 - receptors for, 240
- Kininases, in kidney function, 237
- Kininogens, in kidney function, 237
- Kleihauer-Betke stain, in
 - hemoglobinopathies, 810
- Kostmann's syndrome, neutropenia in, 882-883
- Kwashiorkor, albumin levels in, 357
 - immunodeficiency in, 459
- Laboratory management, quality in, 513-514, 515-524
- Lactic acidosis, 110
- Lactobacillus casei*, in folic acid assay, 377

- Lactobacillus leishmanii*, in vitamin B₁₂ assay, 377
- Lactose, in neonatal nutrition, 393-394
- Lactose tolerance test, 394
- Lasers, in flow cytometry, 832-833
 - in red cell analysis, 775-776
- Laxatives, phosphorus-containing,
 - hyperphosphatemia in, 186
- Lead, determination of, 248
 - kidney function and, 245-248
- Leishman stains, 765
- Length of stay in hospital, nutritional
 - factors in, 495, 499, 503-506
 - predictive models for, 346-348
- Leukemias, diagnosis of, cytochemistry in, 913
 - flow cytometry in, 838-841
 - hairy cell, stains for, 918-919
 - stains for, 913-914, 917-919
 - vs. lymphocytosis, 869-870
 - vs. reactive neutrophilia, 873-874
- Leukocyte(s), aplasia of, neutropenia in, 884
 - in urine sediment, 16-17
- Leukocyte alkaline phosphatase score, 916-917
- Leukocyte ascorbic acid assay, 378-379
- Leukocyte count, instruments for, 819-820
- Leukocyte esterase stains, 917-918
- Leukocyte terminal deoxynucleotidyl transferase, determination of, in
 - nutritional assessment, 461
- Leukotrienes, in kidney function, 241-244
- Lillie stains, 766
- Linoleic acid deficiency, in neonates, 392-393
- Lipid(s), in neonatal nutrition, 392-393
 - metabolic disorders of, nutrition support in, 416
- Lipid peroxides, formation of, in free
 - radical reactions, 467
- Lipogenesis, thyroid hormones in, 553-554
- Lipolysis, thyroid hormones in, 553-554
- Lipoproteins, low-density, oxidation of, in
 - atherogenesis, 475-480
- Literature, on quality management, 523-524
- Lithium therapy, hypercalcemia in, 171
- Lithotripsy, in nephrolithiasis, 232-233
- Liver disease, coagulation disorders in, 957-959
 - hypocalcemia in, 165
 - thyroxine-binding globulin levels in, 588
- Lofenac formula, in phenylketonuria, 419-422
- Low-density lipoproteins, oxidation of, in
 - atherogenesis, 475-480
- Lupus anticoagulant, 962-964
- Lycopene, as antioxidant, 471

- Lymphangiectasia, lymphocytopenia in, 929
- Lymphoblasts, studies of, flow cytometry in, 838-839
- Lymphocyte(s). See also *B lymphocytes*; *T lymphocytes*.
in urine, 17
total count of, in nutritional assessment, 341, 460-461
- Lymphocyte count, 923-924
in reactive lymphocytosis, 863-864
instruments for, 820
- Lymphocytopenia, 923-934
cell counting in, 923-924
lymphoid system kinetics in, 924-925
pathogenesis of, decreased production in, 925-926
increased destruction in, 926-927
multifactorial causes in, 929-930
redistribution in, 927-929
- Lymphocytosis, malignant, vs. benign, 869-870
reactive, 863-870
causes of, 864
immunoblasts in, 869
in cytomegalovirus infections, 867
in HIV infection, 867
in human herpes virus-6 infection, 867
in infectious mononucleosis, 864-866
in toxoplasmosis, 867
in viral infections, 867
lymphocyte counts in, 863-864
mature, 867-869
transient, 868-869
vs. malignant lymphocytosis, 869-870
- Lymphoma, fine-needle aspiration in, 702
hypercalcemia in, 172-173
lymphoblastic, diagnosis of, flow cytometry in, 839
malignant, diagnosis of, flow cytometry in, 841-842
- Lymphoproliferative disorders, diagnosis of, flow cytometry in, 838-842
- Lysine vasopressin, in diabetes insipidus, 147
- Macrocytic anemia, red cell indices in, 781
- Macrothrombocytopenia, mean platelet volume in, 943
- Magnesium, 209-223
absorption of, measurement of, 214
deficiency of (hypomagnesemia), 162-163, 196
determination of, 213-219
distribution of, 211
excretion of, measurement of, 214-215
in cardiovascular function, 209-210
intracellular, determination of, 216-219
regulation of, 211-213
- Magnetic resonance imaging, in nutritional assessment, 336
of thyroid, 722-723
- Major histocompatibility complex antigens, in autoimmune thyroid disease, 690-694
- Malabsorption, correction of, hypercalcemia in, 170
hypophosphatemia in, 193
of carbohydrates, nutrition support in, 423
of fat, in neonates, 393
- Malachowski stains, 762-763
- Malignancy. See *Cancer*.
- Malnutrition, assessment of. See *Nutritional assessment*.
- biochemical, 316
catabolic flow phase of, 366
clinical features of, 317
consequences of, 494
development of, 316-317
ebb phase of, 366
immune function in, 340-341, 457-463
in elderly persons, 348
in severe illness, 366
incidence of, 493
lymphocytopenia in, 926
nutrition support in, costs of, 500-501
criteria for, 494-495
multidisciplinary team for, 501
routes for, 499-500
protein levels in. See *Nutritional assessment, proteins in*.
symptomatic, 317
thyroxine-binding globulin levels in, 589
transthyretin levels in, 591
- Manganese, determination of, in nutritional assessment, 384
in geriatric nutrition, 444-445
in neonatal nutrition, 398-399
- Maple syrup urine disease, nutrition support in, 413
- Maximum tubular transport capacity, 274
- May stains, 764-765
- May-Hegglin anomaly, mean platelet volume in, 943
- MCH (mean cell hemoglobin), 773
- MCHC (mean cell hemoglobin concentration), 773-774
- MCV (mean cell volume), 773-774, 776-778
- Mean cell hemoglobin, 773
- Mean cell hemoglobin concentration, 773-774
- Mean cell volume, 773-774, 776-778
- Mean platelet volume, 937-950
biological significance of, 937-941
clinical utility of, 943-947

- Mean platelet volume (*Continued*)
 methodologic problems with, 941-943
 Measles, lymphocytopenia in, 930
 Mechanical ventilation, muscular weakness
 in, nutrition support in, 342-343
 Medicare, regulatory aspects of, 739-740
 Medullary thyroid carcinoma, 726-727
 fine-needle aspiration in, 703
 prognosis for, 730
 treatment of, 730
 Megaloblastic anemia, in folic acid
 deficiency, 376-377
 neutropenia in, 888
 Membranoproliferative glomerulonephritis,
 serologic evaluation in, 77
 Menaquinone assay, 381
 Menkes' steely hair syndrome, copper
 deficiency in, 397-398
 Metabolic acidosis. *See under Acidosis.*
 Metabolic alkalosis, diagnosis of, 113
 in mixed acid-base disorders, 114
 Metabolic disorders, inborn, 409-434
 categories of, 411
 cofactor-replacement therapy in, 427-
 430
 detoxification therapy in, 430
 dietary formulations for, 430-432
 nutrient prohibition in, 422-427
 nutrient restriction in, 412-422
 prenatal screening for, 411-412
 screening for, 411-412
 of bone, in neonates, 394-395
 Metals. *See also specific metal.*
 trace, in nutritional assessment, 382-384
 Metanephrine, determination of, 295-296
 Metastatic carcinoma, thyroid, fine-needle
 aspiration in, 703
 Methyl violet stain, 912-913
 Methylene blue stains, 760-768, 906-908
 Methylene violet stains, 763-764
 3-Methylhistidine, determination of, in
 nutritional assessment, 335
 Microcytic anemia, differential diagnosis
 of, red cell indices in, 777-781
 mean platelet volume in, 944-945
 Milk, galactosemia and, 422-427
 human, nutrition and, 390-392, 394-397,
 403-404
 Milk-alkali syndrome, 174
 Minerals. *See also specific mineral.*
 as antioxidants, 469
 as oxidants, 469
 in geriatric nutrition, 442-445
 in neonatal nutrition, 394-399
 Minimal residual disease, detection of, flow
 cytometry in, 840-841
 Mithramycin, in hypercalcemia, 176
 Molybdenum, determination of, in
 nutritional assessment, 384
 in geriatric nutrition, 444-445
 in neonatal nutrition, 398-399
 Monoclonal antibodies, in flow cytometry,
 836-838
 Monoclonal antibody tests, in
 hemoglobinopathies, 809
 Monoclonal gammopathy of undetermined
 significance, diagnosis of, flow
 cytometry in, 842
 Monocyte(s), assay of, flow cytometry in,
 845-846
 Monocyte count, instruments for, 820
 Mononucleosis, infectious, 864-866
 Monosaccharide malabsorption, nutrition
 support in, 423
 MSUD diet, in metabolic disease, 420-421,
 431
 Mullen prognostic nutritional index, 320,
 345
 Multidrug resistant gene, flow cytometry
 studies of, 840
 Multiple endocrine neoplasia,
 hypercalcemia in, 170
 Multiple myeloma, diagnosis of, flow
 cytometry in, 842
 hypercalcemia in, 172
 Muscle function, evaluation of, in
 nutritional assessment, 341-343
 Myasthenia gravis, lymphocytopenia in,
 930
 Myeloblasts, detection of, stains for, 913-
 914
 Myeloid cells, flow cytometry studies of,
 836-838
 Myelokathexis, neutropenia in, 882
 Myeloma, multiple, diagnosis of, flow
 cytometry in, 842
 hypercalcemia in, 172
 Myeloperoxidase, detection of, stains for,
 913-914
 Myeloproliferative disorders, vs. reactive
 neutrophilia, 873-874
 Myocardial infarction, mean platelet
 volume in, 947
 Myopathy, in hypophosphatemia, 201
 Necrosis, acute tubular, diagnosis of, 91-92
 Neonates, hypothyroidism in, 645-652
 neutropenia in, 888
 nutrition in, carbohydrates, 393-394
 electrolytes, 390-391
 fluids, 390-391
 lipids, 392-393
 minerals, 394-399
 protein, 391-392
 vitamins, 399-404
 sepsis in, band count in, 898

- Neoplasms. See also *Cancer*.
 transthyretin levels in, 591
- Neopterin, determination of, in
 phenylketonuria, 418
- Nephritic factor of the terminal pathway,
 in glomerulonephritis, 77
- Nephritis, acute interstitial, diagnosis of, 92
- Nephrolithiasis, 225-234
 causes of, 226, 230
 history in, 227-228
 laboratory investigation of, 228-232
 metabolic evaluation of, 226-227
 natural history of, 225-226
 physical examination in, 228
 stone types in, 228
 treatment of, 232-233
- Nephrolithotomy, percutaneous, 232
- Nephron, anatomy of, 3, 7
- Nephrotic syndrome, 27-30
- Net acid excretion test, in renal tubular
 acidosis, 120
- Net charge, urinary, in renal tubular
 acidosis, 120-121
- Neurologic disorders, in
 hypophosphatemia, 201
- Neutral stain, of Ehrlich, 759-760
- Neutron activation analysis, in nutritional
 assessment, 336-337
- Neutropenia, 879-893
 acquired, 884-888
 age-related, 888-889
 autoimmune, 888-889
 bone marrow recovery and, 889-890
 chronic idiopathic, 885
 constitutional, 882-884
 cyclic, 882-883
 definition of, 880
 drug-induced, 882
 evaluation of, 890-891
 in children, 891
 in pediatric patients, 888-889, 891
 mechanisms causing, 881-882
 severity of, 880
 treatment of, 892
- Neutrophil(s), band, counting of. See *Band count*.
 definition of, 895-896
 in urine, 16
- Neutrophilia, reactive, 870-875
 causes of, 870-871
 differential diagnosis of, 873-874, 916-917
 hereditary, 871
 in Down syndrome, 874-875
 kinetic mechanisms in, 871-872
 neutrophil morphology in, 872-873
 toxic, 872
- Newborn infants. See *Neonates*.
- Niacin, assay for, 378
 requirements for, in elderly persons,
 445-446
- Nicotinamide load test, in niacin assay, 378
- Nitric oxide radical, as oxidant, 467
- Nitrogen balance, in elderly persons, 441-442
 in nutritional assessment, 335, 365-366
 transthyretin in, 360
- Nocht stains, 763-764
- Nodules, thyroid. See *Thyroid gland, nodular disease of*.
- Nonthyroid sickness, free thyroxine levels
 in, 614-615
- Norepinephrine, excess of, in hypertension,
 295-297
- Normocytic anemia, red cell indices in, 781
- Nuclear magnetic resonance, in magnesium
 determination, 214
- Nuclear Regulatory Commission,
 laboratory regulations of, 741
- Nutrients, inadequate availability of, 316
 stability of, during testing, 328
- Nutrition. See also *Malnutrition*.
 antioxidants in. See under *Free radicals*.
 deficiencies in, 317
 factors affecting, biologic, 324-325
 drug interactions, 325
 free radicals and. See *Free radicals*.
 immune function and, 457-463
 in elderly persons. See under *Elderly persons*.
 in neonates. See under *Neonates*.
- Nutrition Screening Initiative, 437
- Nutrition support, 313-522
 complications of, prevention of, 501
 costs of, 500-501
 criteria for, 494-495
 delayed, costs of, 498-499
 failure to provide, consequences of, 494
 in cancer prevention, 472-475
 in metabolic disorders, 409-434
 cofactor-replacement therapy, 427-430
 for detoxification, 430
 formulations for, 430-432
 nutrient prohibition in, 422-427
 nutrient restriction in, 412-422
 inadequate, costs of, 498-499
 monitoring of, 318
 routes for, 499-500
 test panels for, 321-324
- Nutritional assessment, 315-329, 331-354
 absorptiometry in, 336
 analytic considerations in, 328-329
 anthropometry in, 333-334
 bioelectrical impedance in, 337-338
 biologic variables in, 324-325
 body composition measures in, 332-340
 clinical, 344-345
 clinical indications for, 501-502

Nutritional assessment (*Continued*)

- complement system in, 461
- computed tomography in, 336
- confirmatory testing in, 318
- delayed hypersensitivity in, 340-341, 345-346, 461
- financial implications model for, 502-504
- functional tests in, 318, 340-343
- global, 343-345, 496-497
- global testing in, 496-497
- goals of, 319-324
- immune function evaluation in, 340-341, 460-462
- in elderly persons, 325, 348, 436-438
- in nutritional therapy monitoring, 318
- indications for, 501-502
- infrared intertance in, 336
- isotope techniques in, 335
- leukocyte terminal deoxynucleotidyl transferase determination in, 461
- magnetic resonance imaging in, 336
- multivariable equations for, 345-346
- muscle function evaluation in, 341-343
- neutron activation analysis in, 336-337
- nitrogen balance in, 335
- potassium content in, 337
- predictive value of, 345-348
- prognostic nutritional index in, 320
- proteins in, 355-371
 - albumin, 338-339, 345-346, 356-357
 - C-reactive, 366
 - fibronectin, 339-340, 364-365
 - interleukins, 366-367
 - nitrogen balance and, 365-366
 - retinol-binding, 360-362
 - somatomedin C, 362-364
 - transferrin, 339, 345-346, 357-358
 - transthyretin, 339, 359-360
 - visceral, 338-340
- reflexive testing in, 497-499
- result interpretation in, 324-329
- screening program for, 504-505
- screening programs in, 319, 437-438, 504-505
- skinfold thickness in, 336, 345-346
- specimen contamination in, 328
- static tests in, 318, 328-329
- subjective, 320
- test panels in, 321-324
- tests for, 317-319
- thymulin in, 462
- timeliness of, 495-496
- total body conductivity in, 337
- trace metal assays in, 382-384
- ultrasound in, 335-336
- underutilization of, 320-321
- urine testing in, 335
- vitamin assays in, 373-381
 - fat-soluble, 379-381

- water-soluble, 374-379
- weight measurement in, 332-333

- Occupational Safety and Health Act, laboratory regulations of, 741-742
- Oncogenous phosphaturia, 196
- Ophthalmopathy, Graves', computed tomography of, 721
- Organic osmolytes, 141-142
- Orthiodohippurate, labeled, in kidney function assessment, 62-64
- Osmolality, sodium balance and, 136
- Osmoles, idiogenic, 141-142
- Osmolytes, organic, 141-142
- Osmometry, in urinalysis, 132
- Osteomalacia, oncogenic, 196
- Osteoporosis, nutritional support in, 442
- Oxalate crystals, in urine, 18
- Oxidation, in carcinogenesis, 472-475
 - of low-density lipoproteins, in atherogenesis, 475-480
- Oxidative stress, cellular damage in, 468
- Oxygen, free radical forms of, 466-468
- Pancreatitis, hypocalcemia in, 165
 - lymphocytopenia in, 928
- Papillary thyroid carcinoma, 726
 - fine-needle aspiration in, 702
 - prognosis for, 729-730
 - treatment of, 730
- Para-aminohippurate, clearance of, 34-38
 - in elderly persons, 272
 - tubular secretion of, 48
- Paralysis, familial hyperkalemic periodic, 152
- Parathyroid hormone, deficiency of. See *Hypoparathyroidism*.
 - determination of, 159-160
 - excess of. See *Hyperparathyroidism*.
 - in calcium homeostasis, 157-158
- Parenteral nutrition, hypophosphatemia in, 199
 - transition from, transthyretin levels in, 360
 - types of, 500
- Pareto diagram, in quality management, 522
- Pathology assistants, regulations on, 992-993
- Pediatric patients. See also *Neonates*.
 - fever in, band count in, 898
 - hypercalcemia in, 174-175
 - kidney function in, assessment of, 257-267
 - neutropenia in, 888-889, 891

- nutrition in, 389-408
 assessment of, somatomedin levels in, 363-364
 phenylketonuria in. *See Phenylketonuria*.
 potassium regulation in, 261-262
 sodium regulation in, 260-261
 urine concentration ability in, 260
 Pentagastrin test, in thyroid cancer, 731-732
 Peripheral smear review, 853-861
 adaptation to other laboratories, 858
 benefits of, 858-861
 cost of, 858
 definition of, 854
 performance of, 855-857
 personnel for, 857
 time required for, 857-858
 tools for, 854-855
 turnaround time for, 857
 Peroxidation, 467
 Personnel, for laboratories, requirements for, 990-991
 standards for, 745-747
 pH, conversion to hydrogen ion, 107-108
 of urine, 14
 in renal tubular acidosis, 119-120
 Phagocytosis, in malnutrition, 459-460
 Phenobarbital, hypocalcemia from, 165
 Phenolsulfonphthalein test, in renal plasma flow determination, 274
 Phenyl-Free formula, in phenylketonuria, 419-422
 Phenylketonuria, differential diagnosis of, 418
 historical aspects of, 410
 nutrition support in, 412, 414, 417-422, 431
 pathophysiology of, 417-418
 screening for, 411
 Pheochromocytoma, hypercalcemia in, 171-172
 hypertension in, 295-297
 Phosphate, determination of, 183-184
 imbalance of, 183-207
 hyperphosphatemia, 165-166, 184-192
 hypophosphatemia, 187, 192-204
 in neonatal nutrition, 394-395
 Phosphate binders, in hyperphosphatemia, 191-192
 Phosphaturia, oncogenic, 196
 Phosphomolybdate, in phosphate determination, 183
 Phosphosoda, in hypophosphatemia, 203
 Phyloquinone assay, 381
 Phytohemagglutinin, in lymphocyte function testing, 341
 Pitressin, in diabetes insipidus, 147
 Pituitary-thyroid axis, free thyroxine-thyrotropin relationships and, 660-661
 thyrotropin production and, 674-676
 Plasma ascorbic acid assay, 378-379
 Plasma cell dyscrasias, diagnosis of, flow cytometry in, 842
 Plasma creatinine, 35-44
 vs. glomerular filtration rate, 42-43
 Plasminogen, assays for, 953
 Platelet(s), age of, volume of, 938-939
 evaluation of, flow cytometry in, 846
 function of, evaluation of, 953-954
 in liver disease, 959
 mean volume of. *See Mean platelet volume*.
 Platelet count, in disseminated intravascular coagulation, 957
 instruments for, 820
 vs. platelet volume, 940-941
 Plehn stains, 762
 Polychrome methylene blue stains, 764-766, 906-907
 Polyethylene glycol precipitation, in immune complex measurement, 71
 Polymyalgia rheumatica, erythrocyte sedimentation rate in, 794-795
 Porphyria, nutrition support in, 415-416
 thyroxine-binding globulin levels in, 589
 Pors-Nielsen method, for glomerular filtration rate determination, 60-61
 Potassium, determination of, in hypertension, 288-289
 distribution of, abnormal, 151-152
 imbalance of, 149-156
 hyperkalemia, 149-153
 hypokalemia, 153-155, 293-294
 regulation of, in pediatric patients, 261-262
 total body, in nutritional assessment, 337
 tubular secretion of, 150
 Potassium chloride, in hypokalemia, 154-155
 Potassium phosphate, in hypophosphatemia, 203-204
 Prealbumin (transthyretin), in nutritional assessment, 339, 359-360
 Pregnancy, free thyroxine levels in, 611-612
 galactosemia in, 425
 glomerular filtration rate in, 38
 inborn metabolic disorders in, 411-412
 thyroxine-binding globulin levels in, 588
 Premature infants, nutrition in, 389-408
 carbohydrates, 393-394
 electrolytes, 390-391
 fluids, 390-391
 lipids, 392-393
 minerals, 394-399
 protein, 391-392
 vitamins, 399-404
 Prematurity, anemia of, 395-396

- Probulcol, in atherogenesis prevention, 478-479
- Proficiency testing, 521
 in hematology, 973-985
 for unregulated analytes, 975
 guidelines for, 975-983
 optimum performance conditions for, 979-980
 postanalytic activities in, 980
 preanalytic aspects of, 975-979
 regulations for, 974-975
 report review in, 980-983
 unacceptable results in, response to, 983
 unsatisfactory scores in, 974-975
 unsuccessful scores in, 975
 regulations on, 974-975, 991-992
 requirements for, 747-749
- Prognostic nutritional index, 320, 345
- Project management tools, for quality control, 522-523
- Proliferation defects, neutropenia in, 881
- Propionic acidemia, carnitine in, 430
- Prostaglandins, estimation of, 244-245
 in kidney function, 241-245
- Prostate gland, status of, 279-286
 prostate specific antigen in, 284-285
 prostatic acid phosphatase in, 279-284
- Prostate specific antigen, determination of, 284-285
- Prostatectomy, irrigation after, hyponatremia in, 139
- Prostatic acid phosphatase, determination of, 279-284
- Protein(s), deficiency of, assessment of. See *Nutritional assessment, proteins in*.
 electrophoresis of, in immune complex measurement, 70
 for thyroid hormone transport. See *Thyroid hormone(s), transport proteins for*.
 in geriatric nutrition, 441-442
 in milk, 391-392
 in neonatal nutrition, 391-392
 in nutritional assessment. See under *Nutritional assessment*.
 in urine. See *Proteinuria; Urine, protein in*.
- Protein C, assays for, 952-953
 deficiency of, 965-966
- Protein S, assays for, 952-953
 deficiency of, 965-967
- Proteinuria, 21-31
 detection of, 22-26
 in nephrotic syndrome, 27-30
 in non-nephrotic range, 26-27
 isolated, 26-27
 orthostatic (postural), 26-27
 pathogenesis of, 21-22
 transient, 26-27
 with normal renal function, 26-27
- Prothrombin time, in disseminated intravascular coagulation, 957
 in liver disease, 960
 with lupus anticoagulant, 962
- Protirelin, 674
- Prussian blue stain, for iron, 908-910
- Pseudohyperkalemia, 149
- Pseudohypoadosteronism, 151
- Pseudohyponatremia, 137
- Pseudohypoparathyroidism, 162, 189
- Pseudopseudohypoparathyroidism, 162
- Pseudovitamin D deficiency, 400
- Psychiatric disorders, thyrotropin measurements in, 678
- Pterin profile, in phenylketonuria, 418
- Public Law 100-587. See *Regulatory and legislative issues, Clinical Laboratory Improvement Amendments of 1988*.
- Pulse radiolysis, in free radical measurement, 471
- Purine nucleoside phosphorylase deficiency, lymphocytopenia in, 926
- 2-Pyridone, in niacin assay, 378
- Pyridoxal 5-phosphate test, in vitamin assay, 376
- Pyridoxine. See *Vitamin B₆*.
- Pyruvate metabolic disease, nutrition support in, 413
- Quality management, 513-514, 515-524
 clinical pathologist attributes and, 516-517
 community concept of, 518
 computers in, 521
 cycle times and, 520-521
 definitions in, 517-518
 education for, 518-519
 implementation of, 519
 in flow cytometry, 847-848
 in hematologic testing, red cell indices in, 776-777
 in hematology, 976-977
 literature on, 523-524
 of erythrocyte sedimentation rate method, 793
 of hematology instruments, 826-827
 peripheral smear review in, 853-861
 philosophy of, 515-516
 planning for, 519
 proficiency testing in, 521
 regulations on, 744-745, 989-990
 statistical quality control in, 519-520
 statistical tools for, 522-523
- Radioassay, for folic acid, 377

- Radioimmunoassay, for DNA antibodies, 74
 for free thyroxine, 615, 654
 for kallikrein-kinin system activity, 240-241
 for prostaglandins, 245
 for prostatic acid phosphatase, 281-283
 for thyroxine-binding globulin, 594
- Radioisotope methods, for kidney function assessment, 44-45, 53-68
 agents for, 55-57, 62
 compartmental analysis in, 57
 effective renal plasma flow, 61-64
 external imaging methods in, 60-61, 63-64
 glomerular filtration rate, 53-61
 sampling methods for, 57, 59-60
 for thyroid gland evaluation, 711-714, 728
- Radiotherapy, in thyroid cancer, 730
 lymphocytopenia in, 927
- Raji-cell assay, for immune complexes, 72-73
- Rapid slide tests, in infectious mononucleosis, 865-866
- Receptors, thyroid hormone. See *Thyroid hormone receptor(s)*.
- Red cell(s). See also *Erythrocyte(s)*.
- Red cell distribution width, 776
 in anemia differential diagnosis, 777-781
- Red cell indices, 773-785
 automated analysis of, 775-776
 derivation of, 774
 history of, 773
 in anemia differential diagnosis, 777-781
 in complete blood count enhancement, 781-782
 in system longitudinal process control, 776-777
- Red cell survival, measurement of, flow cytometry in, 847
- Red cell volume, measurement of, flow cytometry in, 847
- Regulatory and legislative issues, 739-752
 Clinical Laboratory Improvement Act of 1967, 740-741
 Clinical Laboratory Improvement Amendments of 1988, 987-994
 accreditation in, 988-989
 advisory committee for, 750-751
 complexity model in, 744-745
 controversy in, 993
 corrections to, 751
 cytology in, 989
 deemed organizations in, 989
 events leading to, 742-743
 evolution of, 993
 exemptions from, 989
 inspections in, 988-989
 laboratory defined in, 743-744
 pathology assistants in, 992-993
 personnel standards in, 745-747, 990-991
 proficiency testing in, 747-749, 991-992
 quality control in, 749-750, 989-990
 sanctions in, 987-988
 test management in, 750
 waived testing in, 744-745
 workload restrictions in, 989-990
- Department of Health and Human Services in, 741
- Food and Drug Administration in, 741
- hematology instruments, 818-819
 history of, 739-744
- Interstate Quarantine Regulations in, 742
- Medicare as, 739-740
- Nuclear Regulatory Commission in, 741
- Occupational Safety and Health Act in, 741-742
- Resource Conservation and Recovery Act in, 742
- Relative dose-response test, in vitamin A assay, 380
- Renal function, 1-302
- Renal plasma flow. See also *Effective renal plasma flow*.
 measurement of, 33-36
- Renal reserve, 37
- Renal tubular acidosis, 117-129
 acid loading tests in, 121-122
 ammonium chloride loading test in, 121-122
 arginine hydrochloride loading test in, 122
 bicarbonate titration in, 124-125
 buffer loading tests in, 124-126
 calcium chloride loading test in, 122
 diagnosis of, clinical approach to, 126-128
 distal, 117-119
 furosemide test in, 124
 hypocalcemia in, 166
 net acid excretion in, 120
 proximal, 117-119
 sodium sulfate infusion test in, 123
 urinary acidification tests in, 121-126
 urinary anion gap in, 120-121
 urine carbon dioxide partial pressure in, with phosphate infusion, 126
 with urinary alkalization, 125-126
 urine pH in, 119-120
- Renin, in renal function, 8
 tumor secreting, hypertension in, 299
- Renovascular hypertension, 297-299
- Resistance, to thyroid hormones. See under *Thyroid hormone(s)*.
- Resource Conservation and Recovery Act, laboratory regulations of, 742

- Respiration, in acid-base regulation, 105
- Respiratory acidosis, diagnosis of, 113
in mixed acid-base disorders, 114
potassium redistribution in, 152
- Respiratory alkalosis. See under *Alkalosis*.
- Resting energy expenditure, in elderly persons, 439, 441
- Reticular dysgenesis, neutropenia in, 882
- Reticulated platelets, flow cytometry studies in, 846
- Reticulocyte(s), flow cytometry studies of, 847
- Reticulocyte count, instruments for, 823-824
stains for, 907-908
- Retinoid X receptor, 534
- Retinol (vitamin A), assay for, 379-380
in geriatric nutrition, 448-449
in neonatal nutrition, 399-400
- Retinol-binding protein, complex with transthyretin, 359-361
in nutritional assessment, 360-362
- Retinyl esters, in elderly persons, 448-449
in vitamin A assay, 380
- Reuter stains, 765
- Rhabdomyolysis, hyperkalemia in, 152
hyperphosphatemia in, 185-187
hypophosphatemia in, 201
- Rheumatoid arthritis, erythrocyte sedimentation rate in, 794-795
neutrophilia in, 871
- Rh-negative cells, detection of, flow cytometry in, 847
- Riboflavin (vitamin B₂), assay for, 374-375
in geriatric nutrition, 445-446
in metabolic disease, 428
in neonatal nutrition, 402-403
- Rickets, in vitamin D deficiency, 400-401
vitamin D-dependent, hypocalcemia in, 164-165
- Roe stains, 766
- Romanowsky stains, 763
- Romanowsky-Giemsa effect, 766-768
- Run charts, in quality management, 523
- Saline solution, hypertonic, in hyperkalemia, 152
in hypercalcemia, 176
- Sapirstein model, for compartmental analysis, in kidney function assessment, 57
- Sarcoidosis, hypercalcemia in, 173-174
lymphocytopenia in, 928
- Scatter diagrams, in quality management, 523
- Schilling test, in vitamin B₁₂ assay, 377
- Schwachman-Diamond syndrome, neutropenia in, 882
- Screening programs. See also *Wellness testing*.
for inborn metabolic disorders, 411-412
for nutritional assessment, 319, 437-438
- Seabright Bantam syndrome, 564
- Sebastiani syndrome, mean platelet volume in, 945
- Sediment, urinary, analysis of, 16-18
in kidney failure, 93-94
- Sedimentation ratio, Zeta, 792
- Selenium, as antioxidant, 474
determination of, in nutritional assessment, 383-384
in atherogenesis prevention, 480
in geriatric nutrition, 444-445
in neonatal nutrition, 398
- Self-tolerance, autoimmune disease and, 683-685
- Senescence, anemia of, 444
- Sepsis, band count in, 898
mean platelet volume in, 944
- Serologic tests, in infectious mononucleosis, 865-866
- Serology, in kidney function evaluation, 69-87
- Severe combined immunodeficiency, lymphocytopenia in, 925-926
- Sickle cell disease and trait, hemoglobin analysis in, 803-804, 806, 808-809, 811
hyperphosphatemia in, 189
- Silicon, requirements of, in elderly persons, 445
- Spittle's syndrome, hypercalcemia in, 170
- Skin testing, in nutritional assessment, 340-341
- Skinfold thickness, in nutritional assessment, 333-334, 336, 345-346
- Smear, peripheral, review of. See *Peripheral smear review*.
- Smoking, in atherogenesis, 479-480
- Snake bite, lymphocytopenia in, 928
- Sodium, balance of, 135-136
distribution of, 135-136
excretion of, in kidney failure, 94-97
imbalance of, 135-148
hypernatremia, 142-147
hyponatremia, 136-142, 261
vs. normal sodium-water balance, 135-136
regulation of, in pediatric patients, 260-261
- Sodium bicarbonate, in hyperkalemia, 152
- Sodium sulfate infusion test, in renal tubular acidosis, 123
- Somatomedin C, in nutritional assessment, 362-364
- Southeast Iowa Wellness Program, 483-492

- Specific gravity, of urine, 14, 132
- Splenectomy, in neutropenia, 892
- mean platelet volume in, 946
- Stains, in flow cytometry, 835
- in hematologic testing, 759-771, 905-921
- brilliant cresyl blue, 912-913
- Chenzinsky, 760-762
- Ehrlich, 759-760
- eosin, 906-907
- fluorescent, 919
- for Heinz body preparation, 912-913
- for iron, 908-910
- for leukocyte alkaline phosphatase score, 916-917
- for leukocyte esterase, 917-918
- for myeloperoxidase, 913-914
- for reticulocyte enumeration, 907-908
- for tartrate-resistant acid phosphatase, 918-919
- Giemsa, 765-766, 906-907
- Grünwald, 764-765
- history of, 759-760
- immunocytochemical, 919
- in leukemia, 913-914
- Jenner, 764-765
- Leishman, 765
- Lillie, 766
- Malachowski, 762-763
- May, 764-765
- methyl violet, 912-913
- methylene blue, 906-908
- Nocht, 763-764
- Plehn, 762
- Prussian blue, 908-910
- Reuter, 765
- Roe, 766
- Romanowsky, 763
- Romanowsky-Giemsa effect and, 766-768
- Sudan black B, 915-916
- Wilcox, 766
- Wright, 765, 906-907
- Stones, kidney. See *Nephrolithiasis*.
- Streptococcal infection, glomerulonephritis after, 81-82
- Stroke, mean platelet volume in, 947
- Sudan black B stain, 915-916
- Superoxide dismutase, as free radical scavenger, 466, 468-469
- Superoxide radical, 466-468
- Syndrome of inappropriate antidiuretic hormone secretion, hyponatremia in, 138, 142
- Systemic lupus erythematosus, circulating anticoagulants in, 962-964
- lymphocytopenia in, 926-927
- T lymphocytes, flow cytometry studies of, 836-838
- in immunodeficiency, 845
- in leukemia, 839, 841
- in autoimmune thyroid disease, 683-685, 687
- reduction of, in malnutrition, 459
- Tamm-Horsfall protein, 17-18
- Tartrate-resistant acid phosphatase, detection of, 918-919
- Technetium 99m compounds, in kidney function assessment, 56-57, 62-63
- in thyroid imaging, 711, 713
- Temporal arteritis, erythrocyte sedimentation rate in, 794-795
- Test management, regulations on, 750
- Test panels, for nutritional assessment, 321-324
- Tetany, in hyperphosphatemia, 190
- in hypocalcemia, 166
- Tetrahydrobiopterin, in metabolic disease, 428
- in phenylketonuria, 417-418
- Thalassemias. See also *Hemoglobinopathies*.
- hemoglobin composition in, 802-803
- hemoglobin quantitation in, 806, 808
- red cell indices in, 777-781
- Thallium 201, in thyroid imaging, 711, 714
- Theophylline therapy, hypercalcemia in, 171
- Thiamin. See *Vitamin B₁*.
- Thiazin stains, 761, 765-766
- Thiobarbituric acid-reactive substances, in free radical measurement, 472
- Thionin stain, 760
- Thirst, decreased, hypernatremia in, 142, 144
- Thrombocytopenia, congenital, mean platelet volume in, 945-946
- flow cytometry studies in, 846
- mean platelet volume in, 944-945
- Thrombocytosis, from infant formulas, 393
- mean platelet volume in, 945
- Thrombosis, in disseminated intravascular coagulation, 956-959
- Thromboxanes, in kidney function, 241-244
- Thymulin, in nutritional assessment, 462
- Thyroglobulin, antibodies to, 685-686
- in simple goiter, 690
- in thyroid atrophy, 690
- determination of, in thyroid cancer, 728, 731-732
- Thyroid disease, pathophysiology of, 531-752
- Thyroid function testing, automation of, 631-644
- immunoassays for, accuracy of, 639-641
- data management for, 633-634
- disadvantages of, 635
- future trends in, 643

T₄. See *Thyroxine*.

- Thyroid function testing (*Continued*)
 lot-to-lot variation in, 641-642
 method comparison in, 642
 performance evaluation in, 642-643
 precision of, 638
 reagent stability in, 633
 sample management for, 634
 sensitivity of, 638-639
 signal detection in, 634-635
 systems for, 635-638
 type of, 632-633
 for congenital hypothyroidism, 645-652
 transport protein variations effects on, 592-593
- Thyroid gland, atrophy of, 690
 autoimmune disease of, 683-697
 cancer of. See under *Cancer*.
 computed tomography of, 719-722
 diffuse disease of, ultrasonography of, 718
 disease of, mean platelet volume in, 944
 fine-needle aspiration of, 699-709
 imaging for, 716-719
 in cancer diagnosis, 728-729
 ultrasonographic guidance of, 716-719
 imaging of, 711-724
 computed tomography in, 719-722
 for fine-needle aspiration, 716-719
 magnetic resonance in, 722-723
 nuclear techniques in, 711-714
 ultrasound in, 714-719
 magnetic resonance imaging of, 722-723
 nodular disease of, computed tomography of, 720
 fine-needle aspiration in, 701
 ultrasonography of, 716, 718-719
 versus cancer, 725
 nuclear medicine imaging of, 711-714
 physical examination of, 727
 ultrasonography of, 714-719
- Thyroid growth-stimulating antibodies, in Hashimoto's thyroiditis, 689
- Thyroid hormone(s). See also *Thyroxine*.
 determination of, transport protein variations effects on, 592-593
 in thyroid cancer, 727-728
 mechanism of action of, 531-541, 543-561
 at developmental level, 555-556
 central hypothesis for, 531-532
 coordinate, 552-554
 DNA interactions in, 533-535
 gene expression in, 535-536
 historical review of, 543-546
 lipogenesis and lipolysis and, 553-554
 nontranscriptional, 536-538
 nutritional influences on, 552-553
 receptors in. See *Thyroid hormone receptor(s)*.
 thyroid hormone response elements in, 532-533, 535, 550-552
 transcription initiation in, 536
 resistance to, 563-581
 classification of, 564-565
 clinical features of, 566-567
 diagnosis of, 567-571
 etiology of, 571-575
 generalized tissue, 564
 inheritance of, 565-566
 pathophysiology of, 575-577
 peripheral tissue, 565
 inheritance of, 565-566
 pathophysiology of, 575-577
 peripheral tissue, 565
 pituitary, 564
 prevalence of, 565
 tissue changes in, 569-571
 treatment of, 577
 transport proteins for, 583-598
 abnormalities of, detection of, 594-595
 dissociation of, 603-604
 dynamic equilibrium of, 601
 hormone distribution and, 600
 physicochemical properties of, 584-586
 variations in, 586-592
 thyroid function tests affected by, 592-593
- Thyroid hormone auxiliary proteins, 548
- Thyroid hormone receptor(s),
 developmental functions of, 555-556
 DNA interactions of, 533-535
 historical review of, 543-546
 in gene expression, 535-536
 in transcription initiation, 536
 molecular biology of, 546-550
 mutation of, hormone resistance in, 571-577
 tissue distribution of, 548-550
- Thyroid hormone receptor auxiliary proteins, 533-534
- Thyroid hormone response elements, 532-533, 535, 550-552
 in hormone resistance, 571, 575-576
- Thyroid-associated lymphoid tissue, in autoimmune disease, 687
- Thyroidectomy, in thyroid cancer, 730-731
- Thyroiditis, Hashimoto's, autoantibodies in, 689-690
 fine-needle aspiration in, 701
 subacute, fine-needle aspiration in, 701
 ultrasonography of, 718
- Thyroid-stimulating antibodies, in Graves' disease, 687-689
- Thyroperoxidase, autoantibodies to, 686
 in thyroid atrophy, 690
 in thyroiditis, 689-690
- Thyrotoxicosis, hyperphosphatemia in, 189
- Thyrotropin, levels of, versus free thyroxine levels, 660-670
 measurement of, 673-682

- algorithm for, in thyroid disease, 680-681
 - analytic considerations in, 676-677
 - elevated values from, significance of, 679
 - in congenital hypothyroidism screening, 646-648
 - in epilepsy, 678-679
 - in psychiatric disorders, 678
 - in thyroxine replacement therapy, 677-678
 - in thyroxine suppressive therapy, 678
 - pituitary function and, 674-676
 - sensitivity of, 673-674
 - terminology of, 673-674
 - suppression of, monitoring in, 678
 - Thyrotropin receptor, autoantibodies to, 686
 - in Graves' disease, 687-689
 - Thyrotropin-binding immunoglobulin G, 687
 - Thyrotropin-releasing hormone stimulating test, 674-675
 - Thyroxine, determination of, in congenital hypothyroidism screening, 646-648
 - free, 599-629
 - capillary penetration by, 606-611
 - equilibrium of, with bound state, 600-601
 - hypothesis concerning, 599-612
 - basic concepts of, 599-603
 - physicochemical basis of, 603-606
 - physicochemical effects of, 606-611
 - physiologic effects of, 611-612
 - in pregnancy, 611-612
 - measurement of, 612-625, 653-672
 - dialysis techniques for, 613-615, 654-656, 663-667
 - immunoassays in, 615-625
 - in nonthyroidal disorders, 657-658
 - in thyroidal disorders, 658-659
 - in vivo, 656-657
 - methods for, 654-656
 - normal physiology and, 653-654
 - radioimmunoassay, 615, 656
 - radioimmunoassay/dialysis in, 615
 - thyrotropin levels and, 660-670
 - ultrafiltration in, 613-615
 - replacement therapy with, in congenital hypothyroidism, 650
 - thyrotropin monitoring in, 677-678
 - suppressive therapy with, in thyroid cancer diagnosis, 728
 - thyrotropin monitoring in, 678
- Thyroxine-binding globulin, abnormalities of, detection of, 594
 - deficiency of, 586
 - free hormone hypothesis and, 600
 - physicochemical properties of, 584-585
 - variations in, 586-589, 592-593
- Thyroxine-binding prealbumin (transthyretin), in nutritional assessment, 339, 359-360
- TNM classification, of thyroid cancer, 726-727
- α -Tocopherol. *See Vitamin E.*
- Total body conductivity, in nutritional assessment, 337
- Total lymphocyte count, in nutritional assessment, 341
- Total radical-trapping antioxidant parameter method, in free radical measurement, 472
- Total renal plasma flow, calculation of, 35
- Toxic shock syndrome, hypocalcemia in, 166
- Toxoplasmosis, lymphocytosis in, 867
- Trace metal assays, in nutritional assessment, 382-384
- Trade-off hypothesis, in renal failure, 190-191
- Transferrin, in nutritional assessment, 339, 345-346, 357-358
- Transplantation, kidney,
 - hypophosphatemia after, 194
- Transport maximum, in renal tubules, 47-48
- Transport proteins, for thyroid hormones. *See Thyroid hormone(s), transport proteins for.*
- Transthyretin, abnormalities of, detection of, 594-595
 - free hormone hypothesis and, 600
 - in nutritional assessment, 339, 359-360
 - physicochemical properties of, 585-586
 - variations in, 589-593
- TRAP (total radical-trapping antioxidant parameter) method, in free radical measurement, 472
- Triacid stain, 760
- Triene:tetraene ratio, in essential fatty acid deficiency, 392-393
- Triglycerides, determination of, in
 - hypertension, 290-291
 - in neonatal nutrition, 392-393
 - medium-chain, in infant formulas, 393
- Triple phosphate crystals, in urine, 18
- Tryptophan load test, in niacin assay, 378
- in vitamin assay, 376
- TSH. *See Thyrotropin.*
- Tuberculosis, lymphocytopenia in, 927
- Tubules, renal. *See Kidney, tubules of.*
- Tumor lysis syndrome, hyperphosphatemia in, 187-188
- Tumor markers, in thyroid cancer, 728
- Tumor necrosis factor, lymphocytopenia from, 928

- Tumoral calcinosis, hyperphosphatemic, 189
- Turnaround times, in laboratory testing, 520-521
- Tyrosinemia, nutrition support in, 415
- Ulcerative colitis, lymphocytopenia in, 928
- Ultrafiltration, in free thyroxine measurement, 613-615
- Ultrasonography, in nutritional assessment, 335-336
of thyroid, 714-719, 728
for fine-needle aspiration, 716-719
- Unna's polychrome methylene blue stains, 764
- Unstable hemoglobin screen, in hemoglobinopathies, 809
- Urea, determination of, 44, 55
- Urea cycle disease, nutrition support in, 415, 430
- Uremia, clinical signs of, 99
creatinine in, 41-42
hyperphosphatemia in, 190
- Uric acid, determination of, in hypertension, 291
in urine, 18
- Uridyltransferase activity test, in galactosemia, 425
- Urinalysis, 13-20
chemical, 14-16
in hypertension, 291
in kidney failure, 93-94
in nephrolithiasis, 228-229
macroscopic, 14-16
- Urinary acidification tests, in renal tubular acidosis, 121-126
- Urinary sediment, analysis of, 16-18
in kidney failure, 93-94
- Urinary tract, obstruction of, kidney injury in, 263-264
- Urine, albumin in, 14-15
analysis of, in nutritional assessment, 335
anion gap in, in renal tubular acidosis, 120-121
Bence Jones proteins in, 15-16
carbon dioxide partial pressure of, with alkalization, 125-126
casts in, 17-18, 93
colligative properties of, 132
concentration of, 131-134
in elderly persons, 274-275
in pediatric patients, 260
crystals in, 18
dilution of, 131-134
in elderly persons, 275
inadequate, hyponatremia in, 137-138
enzymes in, 15
flow of, in kidney failure diagnosis, 92-93
kallikreins in, 238-239, 241
net charge of, in renal tubular acidosis, 120-121
osmometry of, 132
pH of, 14
in renal tubular acidosis, 119-120
protein in. See also *Proteinuria*.
low-molecular-weight, 15
Tamm-Horsfall, 17-18
specific gravity of, 14, 132
- Vasculitis, with glomerulitis, diagnosis of, 92
- Ves-Matic System, for erythrocyte sedimentation rate, 792
- Viral infections, lymphocytosis in, 867
- Visceral proteins, in nutritional assessment, 338-340, 355-371
- Vitamin(s), as antioxidants, 470-471
assays of, in nutritional assessment, 373-381
in geriatric nutrition, 445-451
in metabolic diseases, 427-430
in neonatal nutrition, 399-404
- Vitamin A (retinol), assay for, 379-380
in geriatric nutrition, 448-449
in neonatal nutrition, 399-400
- Vitamin B₁ (thiamin), assay for, 374-375
in geriatric nutrition, 445-446
in metabolic disease, 428
in neonatal nutrition, 402
- Vitamin B₂ (riboflavin), assay for, 374-375
in geriatric nutrition, 445-446
in metabolic disease, 428
in neonatal nutrition, 402-403
- Vitamin B₆ (pyridoxine), assay for, 374, 376
in geriatric nutrition, 446
in metabolic disease, 427-428
in neonatal nutrition, 403
- Vitamin B₁₂ (cyanocobalamin), assay for, 377
in geriatric nutrition, 446-447
in metabolic disease, 427-428
in neonatal nutrition, 404
- Vitamin C (ascorbic acid), as antioxidant, 470-471, 474-475
assay for, 378-379
in atherogenesis prevention, 479-480
in geriatric nutrition, 447-448
in neonatal nutrition, 403-404
- Vitamin D, assay for, 381
disorders of, hypocalcemia in, 163-165
in geriatric nutrition, 449
in metabolic disease, 428
in neonatal nutrition, 400-401

- intoxication with, hypercalcemia in, 173
 supplementation with, in hypocalcemia, 167-168
- Vitamin D₃, synthesis of, in kidney, 10
- Vitamin E, as antioxidant, 470-471, 474-475
 assay for, 380-381
 in atherogenesis prevention, 479
 in geriatric nutrition, 450
 in metabolic disease, 428
 in neonatal nutrition, 401-402
- Vitamin K, assay for, 381
 deficiency of, in liver disease, 957
 in geriatric nutrition, 450-451
 in neonatal nutrition, 402
- von Willebrand's disease, 952-954
- Waist circumference, in nutritional assessment, 334
- Water, body, sodium balance and, 135-136
- Water intoxication, isotonic, in hypernatremia, 146
- Water load test, for kidney diluting capacity, 133
- Wegener's granulomatosis, antineutrophil cytoplasmic antibodies in, 79-81
- Weight measurement, in nutritional assessment, 332-333
- Wellness testing, 483-492
 benefits of, 489-490
 for hypercholesterolemia, 487-489
 for iron deficiency, 486-487
 ubiquity of, 483-484
- Werner's syndrome, hypercalcemia in, 170
- Westergren erythrocyte sedimentation rate method, 787-788, 792
- Whipple's disease, lymphocytopenia in, 928
- Whooping cough, lymphocytosis in, 867-868
- Wilcox stains, 766
- William's syndrome, hypercalcemia in, 174-175
- Williams-Beuren syndrome, 400-401
- Wilson's disease, 398
- Wintrobe method, for erythrocyte sedimentation rate, 791-792
- Wiskott-Aldrich syndrome, lymphocytopenia in, 927
 mean platelet volume in, 945-946
- Work of breathing, measurement of, 343
- Wright stains, 765, 906-907
- X-ray diffraction, in kidney stone analysis, 229
- Yttrium-169 compounds, in kidney function assessment, 56
- Zeta hematocrit, 792
- Zeta sedimentation ratio, 792
- Zetafuge method, for erythrocyte sedimentation rate, 791-792
- Zinc, deficiency of, lymphocytopenia in, 926
 determination of, in nutritional assessment, 382
 in geriatric nutrition, 444-445
 in neonatal nutrition, 396-397

